AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Rhelion Life Sciences Corp.
Video analysis: TRUFF
All videosNo video analysis for this stock yet. Request one from our team.
News: TRUFF
Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health to Deliver Oral Comments at FDA Public Hearing on the Potential Future Therapeutic Use of Psychedelic Drugs
Sarit Hashkes, President of Filament Health Corp., will provide oral remarks at the United States Food and Drug Administration public hearing "Considerations for Potential Future Therapeutic Use of Psychedelic Drugs", being held later today, September 14, 2026 Toronto, Ontario--(Newsfile Corp. - September 14, 2026) - Rhelion Life Sciences Corp. (CSE: RHEL) (FSE: 4YX0) (OTCQB: TRUFF) ("Rhelion" or the "Company"), an Ontario-based organization advancing innovation and research within the legal psychedelic sector, is pleased to announce that Sarit Hashkes, President of its wholly owned subsidiary Filament Health Corp. ("Filament"), will deliver oral comments at the United States Food and Drug Administration ("FDA") public hearing on Considerations for Potential Future Therapeutic Use of Psychedelic Drugs, being held virtually and in person today, September 14, 2026. The hearing has been convened by FDA's Center for Drug Evaluation and Research to gather input on the development, evaluation and potential future therapeutic use of psychedelic drugs.
Rhelion Life Sciences Announces Filament Health is Planning a Stability Program for IBEX011, Its Naturally Derived Ibogaine Drug Candidate
Filament Health has begun planning a stability program for IBEX011, its naturally derived botanical ibogaine drug candidate, in response to growing demand for GMP quality, standardized ibogaine for clinical research. Toronto, Ontario--(Newsfile Corp. - September 10, 2026) - Rhelion Life Sciences Corp. (CSE: RHEL) (FSE: 4YX0) (OTCQB: TRUFF) ("Rhelion" or the "Company") an Ontario-based organization advancing innovation and research within the legal psychedelic sector.
Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Completes Shipment of PEX010 to Australia for University of Melbourne Trial of Psilocybin-Assisted Physiotherapy in Functional Neurological Disorder
Filament Health's patented, naturally derived psilocybin drug candidate PEX010 has been shipped to Austin Health in Melbourne for PSI-PHY, an investigator initiated pilot trial of psilocybin-assisted physiotherapy in refractory motor functional neurological disorder, sponsored by The University of Melbourne and funded by the Australian Government's Medical Research Future Fund The study is the first trial of PEX010 in a movement disorder and, to the Company's knowledge, the first anywhere to combine a psychedelic with physiotherapy Toronto, Ontario--(Newsfile Corp. - September 8, 2026) - Rhelion Life Sciences Corp. (CSE: RHEL) (FSE: 4YX0) (OTCQB: TRUFF) ("Rhelion" or the "Company"), an Ontario-based organization advancing innovation and research within the legal psychedelic sector, is pleased to announce that its wholly owned subsidiary, Filament Health Corp. ("Filament"), has completed the export of PEX010, its patented, standardized, GMP manufactured botanical psilocybin drug candidate, from Canada to Australia in support of an investigator initiated clinical trial. The trial, known as PSI-PHY, investigates psilocybin-assisted physiotherapy in adults with refractory motor functional neurological disorder ("FND").
Rhelion Life Sciences Confirms Further Delivery of Filament Health's PEX010 to Germany's First Psilocybin Compassionate Use Program
Filament Health has completed a further international delivery of its patented, naturally derived psilocybin drug candidate PEX010 to Germany, supporting the first compassionate use program for psilocybin in the European Union The Company believes the continued delivery demonstrates Filament's ability to manufacture, release and supply pharmaceutical-grade botanical psilocybin across international regulatory jurisdictions as new legal access pathways emerge Rhelion intends to leverage Filament's existing GMP manufacturing infrastructure, regulatory experience, intellectual property and international supply capabilities to pursue future commercial supply opportunities as regulated psilocybin markets and patient-access programs develop globally Toronto, Ontario--(Newsfile Corp. - September 3, 2026) - Rhelion Life Sciences Corp. (CSE: RHEL) (FSE: 4YX0) (OTCQB: TRUFF) ("Rhelion" or the "Company"), an Ontario-based organization advancing innovation and research within the legal psychedelic sector, is pleased to announce that its wholly owned subsidiary, Filament Health Corp. ("Filament"), has completed a further delivery of PEX010, its patented, standardized, GMP-manufactured botanical psilocybin drug candidate, to the Central Institute of Mental Health ("CIMH") in Mannheim, Germany. Germany's compassionate use program for psilocybin in treatment-resistant depression is the first program of its kind in the European Union and represents an important precedent for regulated patient access to psilocybin outside of clinical trials.
Rhelion Life Sciences Reports First Quarter 2027 Results
Toronto, Ontario--(Newsfile Corp. - August 31, 2026) - Rhelion Life Sciences Corp. (CSE: RHEL) (FSE: 4YX0) (OTCQB: TRUFF) ("Rhelion" or the "Company"), an Ontario-based organization advancing innovation and research within the legal psychedelic sector, is pleased to report its financial and operational results for the three months ended June 30, 2026 ("Q1 2027"), capping a transitional quarter which culminated in the acquisition of Filament Health Corp. ("Filament"). All figures are reported in Canadian dollars.
Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Issued New United States Patent, Extending the Broadest Natural Psilocybin Patent Estate
A new United States patent, "Dephosphorylation-Controlled Extraction of Phosphorylatable Psychoactive Alkaloids," issued this month, adding to the intellectual property estate behind PEX010, the standardized natural psilocybin drug candidate supporting more than 80 studies worldwide. Toronto, Ontario--(Newsfile Corp. - August 27, 2026) - Rhelion Life Sciences Corp. (CSE: RHEL) (FSE: 4YX0) (OTCQB: TRUFF) ("Rhelion" or the "Company") an Ontario-based organization advancing innovation and research within the legal psychedelic sector.
Rhelion Life Sciences Wholly Owned Subsidiary Filament Health Completes Shipment of PEX010 for University of Washington Phase 2a Trial in Cancer-Related Anxiety and Depression
Filament Health's patented, naturally derived psilocybin drug candidate PEX010 will be supplied to an investigator initiated Phase 2a study evaluating a group retreat model of psilocybin therapy in people living with metastatic solid tumors or incurable hematologic malignancies. Toronto, Ontario--(Newsfile Corp. - August 25, 2026) - Rhelion Life Sciences Corp. (CSE: RHEL) (FSE: 4YX) (OTCQB: TRUFF) ("Rhelion" or the "Company") an Ontario-based organization advancing innovation and research within the legal psychedelic sector.
Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Signs Letter of Intent with Darmiyan, Inc. to Explore Use of FDA De Novo Authorized BrainSee(R) AI Platform in Early Alzheimer's Disease Trial Design
Collaboration looks to explore the use of Darmiyan's FDA De Novo authorized BrainSee® imaging platform, authorized for predicting risk of progression to Alzheimer's disease in patients with amnestic mild cognitive impairment, as well as Darmiyan's core technology, the Virtual Microscope, tailored towards use in pharmaceutical clinical trials The goal of the collaboration is to inform the identification, selection and monitoring of the best candidates for clinical trials of PEX010, Rhelion's patented, naturally derived psilocybin drug candidate Toronto, Ontario--(Newsfile Corp. - August 20, 2026) - Rhelion Life Sciences Corp. (CSE: RHEL) (FSE: 4YX) (OTCQB: TRUFF) ("Rhelion" or the "Company"), an Ontario-based organization advancing innovation and research within the legal psychedelic sector, is pleased to announce that its wholly owned subsidiary, Filament Health Corp. ("Filament"), has entered into a non-binding letter of intent (the "LOI") with Darmiyan, Inc. ("Darmiyan"), a San Francisco based brain technology company, to explore a collaboration combining Darmiyan's artificial intelligence brain imaging platform with PEX010, Filament's patented, standardized, GMP manufactured natural psilocybin drug candidate. Darmiyan is the developer of BrainSee, which in January 2024 received marketing authorization from the U.S. Food and Drug Administration ("FDA") through the De Novo pathway, following the granting of FDA Breakthrough Device Designation in 2021.
